A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
- Conditions
- HIV Infections
- Registration Number
- NCT00002117
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
To investigate the appropriate zalcitabine ( dideoxycytidine; ddC ) dose and zidovudine ( AZT ) schedule for use in combination therapy in patients with HIV infection.
- Detailed Description
Patients are randomized to one of four treatment arms. ddC is administered at 1 of 2 doses every 8 hours. AZT is administered at 1 of 2 doses (every 4 hours while awake or every 8 hours).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 528
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (24)
Kaiser Foundation Hosp
🇺🇸Harbor City, California, United States
Kaiser Permanente Med Ctr
🇺🇸Los Angeles, California, United States
Sharp Rees - Stealy Med Group
🇺🇸San Diego, California, United States
UCSF - San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
Denver Public Health Dept / Disease Control Services
🇺🇸Denver, Colorado, United States
Howard Univ
🇺🇸Washington, District of Columbia, United States
Veterans Administration Med Ctr
🇺🇸Washington, District of Columbia, United States
Miami Veterans Administration Med Ctr
🇺🇸Miami, Florida, United States
Univ of Miami School of Medicine
🇺🇸Miami, Florida, United States
Intergrated Care Ctr
🇺🇸Atlanta, Georgia, United States
Scroll for more (14 remaining)Kaiser Foundation Hosp🇺🇸Harbor City, California, United States